title: A randomized controlled study into the efficacy and toxicity of pegylated liposome encapsulated doxorubicin as an adjuvant therapy in dogs with splenic haemangiosarcoma.
abstract: Safety and efficacy of pegylated liposome encapsulated doxorubicin (PL-DOX) was compared with free doxorubicin as an adjuvant monotherapy in dogs with splenic haemangiosarcoma after splenectomy in a randomized prospective clinical trial. A total of 17 dogs in each group were treated. No significant difference in survival between the two treatments was found. The calculated median overall survival time for the 34 dogs was 166 days [95% confidence interval (CI) 148-184]. The ½ year and one-year survival was 41.2% (95% CI 24.8-56.9) and 22.7% (95% CI 9.9-37.4), respectively. In dogs treated with PL-DOX, a desquamating dermatitis like palmar-plantar erythrodysesthesia (PPES) was seen in two dogs, while three other dogs showed anaphylactic reactions. Cardiotoxicity was not seen in either treatment groups.
authors.affiliation: Department of Clinical Sciences of Companion Animals, Utrecht University, Utrecht, The Netherlands. e.teske@uu.nl
authors.forename: E
authors.initials: E
authors.lastname: Teske
authors.forename: G R
authors.initials: GR
authors.lastname: Rutteman
authors.forename: J
authors.initials: J
authors.lastname: Kirpenstein
authors.forename: J
authors.initials: J
authors.lastname: Hirschberger
mesh_terms: D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000592:standards / Q000633:toxicity*; D059186:Chemoradiotherapy, Adjuvant / Q000662:veterinary; D004283:Dog Diseases / Q000188:drug therapy*; D004285:Dogs; D004317:Doxorubicin / Q000031:analogs & derivatives* / Q000592:standards / Q000633:toxicity*; D005260:Female; D005858:Germany; D006394:Hemangiosarcoma / Q000188:drug therapy / Q000662:veterinary*; D008297:Male; D011092:Polyethylene Glycols / Q000592:standards / Q000633:toxicity*; D013160:Splenic Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000662:veterinary*; D016019:Survival Analysis
chemical_list: D000903:Antibiotics, Antineoplastic; C506643:liposomal doxorubicin; D011092:Polyethylene Glycols; D004317:Doxorubicin